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Research priorities for elimination of visceral leishmaniasis 
Now is a good time to reconsider research priorities 
as 2015 approaches, the target date originally set 
for elimination of visceral leishmaniasis. Visceral 
leishmaniasis is one of the most deadly parasitic 
diseases and disproportionately aﬀ ects the poorest 
and most vulnerable populations. An estimated 
200 000–400 000 people contract visceral leishmaniasis 
every year in developing countries. Spread by sandﬂ ies, 
visceral leishmaniasis can be fought with existing 
interventions, including treatment and vector control, 
but, similarly to every other human parasitic disease, no 
eﬀ ective vaccine exists. 
The elimination target established in 2005 at the 
World Health Assembly is 1 case in 10 000 in all endemic 
areas of the Indian subcontinent. Nepal and Bangladesh 
most notably have reached or are close to reaching 
the elimination target, and India continues to make 
impressive progress. Probably the most important 
achievement in these countries during the past 5 years 
has been the eﬀ ective introduction of point-of-care 
diagnostics and treatment for visceral leishmaniasis at 
the government primary health-care level. Previously, 
treatment was most often sought from unqualiﬁ ed 
medical personnel or distant district tertiary and 
private hospitals. Reaching the elimination of visceral 
leishmaniasis in the Indian subcontinent is clearly now 
a potential reality; however, additional interventions 
are needed to reduce transmission sustainably, and an 
improved understanding of the changing epidemiology 
is needed as the number of cases reduces. 
It is now necessary for experts and policy makers 
to deﬁ ne research priorities, establish who is doing 
what, and identify technology gaps. WHO-TDR (Special 
programme for Research and Training in Tropical 
Diseases) has been supporting visceral leishmaniasis 
elimination related programmes on the ground for more 
than 15 years through development and implementation 
of treatments and diagnostics that are widely used 
today and developing case detection and novel vector 
control strategies that have been used by the national 
programmes. WHO-NTD (Neglected Tropical Diseases) 
has also shown strong leadership in developing 
guidelines to control leishmaniasis worldwide1 and also 
supporting the implementation of visceral leishmaniasis 
interventions. WHO is therefore uniquely positioned to 
continue playing a lead stewardship part to reach and 
sustain elimination of visceral leishmaniasis.
Several priorities will need both basic and 
implementation research approaches. With respect to 
treatment, several eﬀ ective treatment options now 
exist, but a short-course, aﬀ ordable oral drug that 
could be used in combination with existing drugs 
would represent a welcome addition. Implementation 
research is, however, necessary to establish how best 
to use existing treatments under ﬁ eld conditions and 
at a scale that will have a high rate of compliance. 
Implementation research is also needed to establish 
how best to carry out vector control and case detection 
in endemic villages without placing an additional load 
on local health systems and using existing human 
resources and government infrastructure. 
Research is needed to improve understanding of the 
human reservoir and what part asymptomatic infections 
play in transmission. Longitudinal studies of patients 
with visceral leishmaniasis, asymptomatic cases, 
and their household contacts are needed to identify 
biomarkers for disease progression and transmission. 
An improved understanding of the role of post-kala-
azar dermal leishmaniasis in disease transmission is also 
needed because this is a diﬃ  cult condition to treat and 
in some cases treatment might not be justiﬁ ed. A simple 
test to quantify parasite load from small quantities 
of blood is needed to identify those people who are 
infected and at risk of developing and transmitting 
visceral leishmaniasis, and also to provide a test of 
cure and relapse. Xenodiagnosis studies to establish 
whether post-kala-azar dermal leishmaniasis and 
asymptomatic infections transmit parasites to sandﬂ ies 
are necessary to understand disease transmission and to 
develop public health policy. Understanding Leishmania 
biochemical pathways crucial for its survival in visceral 
organs will help researchers to understand pathogenesis 
and might provide insights leading to improved 
treatment interventions.  
A prophylactic vaccine would be the best way to 
consolidate elimination and possibly eradication 
of visceral leishmaniasis. There is good reason to 
believe that a vaccine is feasible because people who 
recover from visceral leishmaniasis after treatment 
develop protective immunity against subsequent 
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visceral leishmaniasis. Studies that focus on the 
human immune response are needed to understand 
why people who are cured have protective immunity 
and why most people who become infected do not 
develop disease. This will help to establish whether 
candidate vaccines induce the correct type of 
protective immunity. With respect to therapeutic 
vaccines, we could argue that treatment of visceral 
leishmaniasis with one dose of liposomal amphotericin 
B can be thought to be a therapeutic vaccine in the 
Indian subcontinent because this results in a cure 
and protective immunity to reinfection. The greatest 
immediate need for a therapeutic vaccine is to treat 
post-kala-azar dermal leishmaniasis because this is 
much more diﬃ  cult to treat than visceral leishmaniasis. 
Such a vaccine might also represent a good ﬁ rst 
step in the development of a prophylactic visceral 
leishmaniasis vaccine and its eﬃ  cacy would be easier to 
monitor through the resolution of the skin lesions.
These research activities will need multidisciplinary 
collaborative eﬀ orts from clinicians, public health 
specialists, and basic science researchers working with 
patients, experts, and policy makers from the endemic 
countries. Coordination of these multidisciplinary 
eﬀ orts will need as much consideration as the science 
itself. Now is the time to do this because elimination of 
visceral leishmaniasis is within reach. 
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